ReviewQatar medical journal2026
Emerging insights into Panton-Valentine leukocidin-producing methicillin-resistant
Review in Qatar medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Panton-Valentine leukocidin (PVL)-producing methicillin-resistant Objectives: To review the prevalence, molecular characteristics, and antibiotic resistance patterns of PVL-positive MRSA strains in GCC countries, i.e., Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates (UAE). Methods: We conducted a scoping review of studies published between January 2020 and December 2025 following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. Searches were performed in PubMed, EMBASE, Scopus, Cochrane Library, and Google Scholar, targeting original research reporting PVL presence in clinical MRSA isolates from GCC countries. Data were extracted into standardized forms and organized in comparative tables. Results: Fourteen original studies were included, primarily from Saudi Arabia, Kuwait, UAE, Bahrain, and Qatar. Across included studies, PVL prevalence among MRSA isolates varied widely, ranging from 0% to 62% depending on country, setting, and study design. Community-associated (CA) MRSA clones, such as ST80-IV, ST30-IV, and ST6-IV, predominated among PVL-positive strains, though PVL acquisition by hospital-associated (HA) lineages like ST22-IV and ST239-III was increasingly reported. PVL-positive strains exhibited resistance to fusidic acid, fluoroquinolones, and macrolides, but remained susceptible to vancomycin and linezolid. Conclusion: PVL-producing MRSA is a significant contributor to staphylococcal disease in the GCC, with prevalence in both community and hospital settings. The convergence of virulence and multidrug resistance among PVL-MRSA strains presents challenges for infection control. Strengthened regional surveillance, standardized molecular typing, and one-health-informed monitoring are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.